{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-362387","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2021-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:11.799265+00:00","generated_at":"2026-06-27T23:35:59.068049+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alnylam appoints Yvonne Greenstreet as CEO effective Jan 1, 2022; discloses compensation","bullets":["Yvonne Greenstreet, formerly President and COO, becomes CEO on Jan 1, 2022.","Annual base salary of $850,000; target bonus 100% of base salary for 2022 performance year.","Initial equity: $5M stock option granting on Dec 31, 2021; additional $2.5M option and $7.5M PSUs in Feb 2022.","$250,000 one-time relocation cash award with repayment obligation if termination for cause within 24 months.","Severance: pre-Change-in-Control no cash severance but continued vesting for 2 years; post-CIC double trigger with 2x salary+bonus and full acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-362387","json":"https://secwatch.observer/filing/0001193125-21-362387.json","markdown":"https://secwatch.observer/filing/0001193125-21-362387.md","text":"https://secwatch.observer/filing/0001193125-21-362387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312521362387/0001193125-21-362387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312521362387/d163524d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T23:35:59.068049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b262d917f1","claim":"Yvonne L. Greenstreet was appointed as Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"Yvonne L. Greenstreet, MBChB, MBA, Alnylam Pharmaceuticals, Inc.’s (the “Company”) current President and Chief Operating Officer, has been appointed Chief Executive Officer of the Company effective January 1, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312521362387/0001193125-21-362387-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}